Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
Date:3/25/2009

2008 2008 (Note 4) Revenues 2,018 8,349 Cost of revenues (6,395) (19,627) Gross loss (4,377) (11,278) Selling and marketing expenses (79) (291) General and administrative expenses (253) (515) Impairment charges (49,581) (49,581) Loss before income taxes (54,290) (61,665) Income tax benefit 9,678 12,413 Loss on discontinued operations (44,612) (49,252) WUXI PHARMATECH (CAYMAN) INC. RECONCILIATION OF GAAP TO Non-GAAP (in thousands of U.S. dollars, except ADS data and par value data) Three Months Ended Year Ended December 31, December 31, 2008 2007 % 2008 2007 % (Note 4) Total company revenue: GAAP revenue from continuing operations 64,448 37,095 74% 253,485 135,205 87% Adjustments: Revenue from discontinued operations (Note 1) 2,018 -- 8,349 -- Total company revenue 66,466 37,095 79% 261,834 135,205 94% Continuing operations: GAAP gross profit 20,274 15,912 27% 96,342 62,858 53% GAAP gross margin 31% 43% 38% 46% Adjustments: Share-based Compensation 1,004 349 3,020 2,069 Amortization of acquired
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
3. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
4. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
5. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
6. Pharmatech 2.0: Introducing Pharmatech Oncology
7. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. WuXi PharmaTech Announces Third Quarter 2008 Results
10. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
11. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...NTACRUZ,Calif.,Nov.24/PRNewswire/--Twomoreprestigi...,sleadingonlinejobboardandcareerssiteforlifescienc...rsityarenowmembersofthejobboard,joining28othermajo...d, www.biocareercenter.com ,isonlyforpost-graduate...ncecareersitesontheInternet,BioCareerCenteristheon...
(Date:11/24/2009)...YKJAVIK,Iceland,November24/PRNewswire-FirstCall/--...hatithasreceivednoticefrom,theNasdaqStockMarkettha...sofNovember30,2009andaForm25-NSEwillbefiledwiththe...CODE,scommonstock,fromlistingonNasdaq,unlessthecom...Panel.Thecompanyhasfiledsuchanappeal,which,willsta...
(Date:11/24/2009)... Health care employment grew by 2...nly one to show consistent growth during the U.S. ...s remain in trouble, and health systems are coming...l, instead of just administrators. , ...re employment continued growing in October despite...
(Date:11/24/2009)...ANGHAI,Nov.24/PRNewswire-Asia/--NODPharmaceuticals...hasallowedthepatentapplicationfor,itsnano-particle...sahighlyefficientapproachtoincorporatepeptidesor,p...eliveryofdrugs,otherwiseadministeredasinjections.N...tomanymacromoleculardrugssuchasinsulin,interferon,...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
...ls,Inc. (Nasdaq: CADX ), a biopharmaceutical comp...ializing proprietary product candidates principall... that the company,s,President and CEO Theodore Sch...ew on Tuesday, October 28, 2008 at 9:30am Pacific ...stor Conference at the Hyatt Aventine,La Jolla Hot...
...nounced that it,has provided a GOLD facility for t...) by MTS Health Investors, LLC (MTS). GOLD financi...cilities. Terms of the,transaction were not disclo...e largest and most reputable,DNA testing laborator...dentification testing for the private sector. The ...
...esults (all percentage comparisons are to comparab... Consistent Research Sales Gain: Q3 2008 sales ...3.1% to organic growth of 4.3%. Q3 organic sal...ased sales units was in-line with the 6.9% gain fo...ncy adjusted sales for SAFC decreased by 2.0% ...
Other Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIOCOM Investor Conference 2Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 11Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 12Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 13Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 14Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 15Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 16Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 17Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 18Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 19Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 20
(Date:11/25/2009)..., police officers and ambulance workers faced a te...omplex. They battled to save people from the colla... fires and evacuated as many people as they could ...ple. And making their jobs even harder was the pro...d their relatives jammed mobile networks with call...
(Date:11/25/2009)...y be just as vital to your health as what you eat,...gical Studies. Their experiments in mice revealed ...enes in the liverthe body,s metabolic clearinghous...e body,s circadian clock as conventional wisdom ha...y of a large number of genes completely independen...
(Date:11/24/2009)... flabby arteries from collapsing have been true li...no longer needed -- once the arteries are strength... had no choice but to leave them in place. , Pro...tment of Biomedical Engineering has developed a ne... where they,re needed, then dissolves. , "Our ne...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 1Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 2Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 3Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 1Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 2Is your environment damaging your health 3F New center aims to find out 47466 1Is your environment damaging your health 3F New center aims to find out 47466 2Is your environment damaging your health 3F New center aims to find out 47466 3
...The cell-signaling molecule Akt is a primary trigg...rface to begin growing vertically beneath the skin... have found. Understanding this key molecular dif...e surface of the skin and melanomas that grow vert...r the development of drugs to treat individuals wi...
...A popular game fish mistaken by scientists for a d...ong the reefs of the Abrolhos region of the South ...l Zootaxa announced the discovery of Lutjanus alex...Lutjanidae family, by researchers Rodrigo Moura of...an of Environmental Defense. The study published i...
...A UCL (University College London) study has found ... not think too hard and instead trust your instinc...urnal Current Biology, shows that, in some cases, ...decisions taken using higher-level cognitive proce...dd one out on a screen covered in over 650 identic...
Other Biology News:Molecular differences between early and advanced melanomas could provide new drug targets 2New species of snapper discovered in Brazil 2Trusting your instincts leads you to the right answer 2Trusting your instincts leads you to the right answer 3
Mouse Anti-Human Cystatin A Monoclonal Antibody, Unconjugated, Clone 224705 from R&D Systems
Acc I from Takara Mirus Bio
Microlite 2+ Plate from Thermo Scientific
... low temperature freezers offer a superior sample ...samples with high capacities. Innovative insulatio... excellent warming protection and ensure low energ...fy tracking of sample location and maximize sample...
Biology Products: